• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Incidence of heparin-induced thrombocytopenia in patients with 2019 coronavirus disease.

作者信息

Lozano Roberto, Franco María-Esther

机构信息

Hospital Real de Nuestra Señora de Gracia, Servicio de Farmacia, Zaragoza, Spain.

Hospital Real de Nuestra Señora de Gracia, Servicio de Hematología, Zaragoza, Spain.

出版信息

Med Clin (Engl Ed). 2020 Nov 13;155(9):409-410. doi: 10.1016/j.medcle.2020.05.023. Epub 2020 Oct 9.

DOI:10.1016/j.medcle.2020.05.023
PMID:33072866
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7546183/
Abstract
摘要

相似文献

1
Incidence of heparin-induced thrombocytopenia in patients with 2019 coronavirus disease.2019冠状病毒病患者肝素诱导的血小板减少症的发病率
Med Clin (Engl Ed). 2020 Nov 13;155(9):409-410. doi: 10.1016/j.medcle.2020.05.023. Epub 2020 Oct 9.
2
Incidence of heparin-induced thrombocytopenia in patients with 2019 coronavirus disease.2019冠状病毒病患者肝素诱导的血小板减少症的发病率
Med Clin (Barc). 2020 Nov 13;155(9):409-410. doi: 10.1016/j.medcli.2020.05.041. Epub 2020 Jul 28.
3
Incidence of heparin-induced thrombocytopenia and therapeutic strategies in pediatric cardiac surgery.小儿心脏手术中肝素诱导的血小板减少症的发生率及治疗策略
Ann Thorac Surg. 2005 Jan;79(1):62-5. doi: 10.1016/j.athoracsur.2004.07.002.
4
Heparin-induced thrombocytopenia in cardiac surgery: Incidence, costs, and duration of stay.心脏手术中的肝素诱导的血小板减少症：发生率、成本和住院时间。
Surgery. 2018 Dec;164(6):1377-1381. doi: 10.1016/j.surg.2018.07.013. Epub 2018 Sep 11.
5
Heparin-Induced Thrombocytopenia and Cardiac Surgery.肝素诱导的血小板减少症与心脏手术。
Semin Thorac Cardiovasc Surg. 2019;31(3):335-344. doi: 10.1053/j.semtcvs.2018.10.011. Epub 2018 Nov 15.
6
Incidence and Outcomes of Heparin-Induced Thrombocytopenia in Patients Undergoing Vascular Surgery.血管手术患者肝素诱导的血小板减少症的发生率及预后
J Cardiothorac Vasc Anesth. 2017 Oct;31(5):1751-1757. doi: 10.1053/j.jvca.2017.05.024. Epub 2017 May 17.
7
Heparin-induced thrombocytopenia among patients of a comprehensive cancer center.一家综合癌症中心患者中的肝素诱导的血小板减少症
SAGE Open Med Case Rep. 2014 Jul 31;2:2050313X14533945. doi: 10.1177/2050313X14533945. eCollection 2014.
8
Incidence of heparin-induced thrombocytopenia type II and postoperative recovery of platelet count in liver graft recipients: a retrospective cohort analysis.肝移植受者肝素诱导的血小板减少症 II 型的发生率和血小板计数术后恢复：回顾性队列分析。
J Surg Res. 2014 Jan;186(1):429-35. doi: 10.1016/j.jss.2013.08.034. Epub 2013 Sep 25.
9
A prospective study on the incidence and clinical relevance of heparin-induced antibodies in patients after vascular surgery.一项关于血管手术后患者肝素诱导抗体的发生率及其临床相关性的前瞻性研究。
Thromb Res. 2000 Mar 15;97(6):387-93. doi: 10.1016/s0049-3848(99)00198-x.
10
Is the incidence of heparin-induced thrombocytopenia affected by the increased use of heparin for VTE prophylaxis?肝素诱导的血小板减少症的发生率是否受 VTE 预防中肝素使用增加的影响？
Chest. 2012 Nov;142(5):1175-1178. doi: 10.1378/chest.11-2926.

引用本文的文献

1
Heparin-Induced Thrombocytopenia in COVID-19: A Systematic Review.新型冠状病毒肺炎中的肝素诱导的血小板减少症：一项系统评价
Anesth Essays Res. 2021 Oct-Dec;15(4):341-347. doi: 10.4103/aer.aer_151_21. Epub 2022 Mar 8.
2
Untangling the Intricacies of Infection, Thrombosis, Vaccination, and Antiphospholipid Antibodies for COVID-19.解析新冠病毒感染、血栓形成、疫苗接种和抗磷脂抗体之间的复杂关系
SN Compr Clin Med. 2021;3(10):2093-2108. doi: 10.1007/s42399-021-00992-3. Epub 2021 Jun 22.
3
Elucidating the Interactions Between Heparin/Heparan Sulfate and SARS-CoV-2-Related Proteins-An Important Strategy for Developing Novel Therapeutics for the COVID-19 Pandemic.阐明肝素/硫酸乙酰肝素与SARS-CoV-2相关蛋白之间的相互作用——开发针对COVID-19大流行的新型疗法的重要策略。
Front Mol Biosci. 2021 Jan 25;7:628551. doi: 10.3389/fmolb.2020.628551. eCollection 2020.
4
COVID-19 patients often show high-titer non-platelet-activating anti-PF4/heparin IgG antibodies.COVID-19 患者常表现出高滴度非血小板活化抗 PF4/肝素 IgG 抗体。
J Thromb Haemost. 2021 May;19(5):1294-1298. doi: 10.1111/jth.15262. Epub 2021 Apr 7.

本文引用的文献

1
High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients.抗凝治疗的重症 COVID-19 患者中静脉血栓栓塞事件发生率高。
J Thromb Haemost. 2020 Jul;18(7):1743-1746. doi: 10.1111/jth.14869. Epub 2020 May 27.
2
Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy.抗凝治疗与伴有凝血功能障碍的严重 2019 冠状病毒病患者的死亡率降低相关。
J Thromb Haemost. 2020 May;18(5):1094-1099. doi: 10.1111/jth.14817. Epub 2020 Apr 27.
3
Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.肝素诱导的血小板减少症：识别、治疗与预防：第七届美国胸科医师学会抗栓与溶栓治疗会议
Chest. 2004 Sep;126(3 Suppl):311S-337S. doi: 10.1378/chest.126.3_suppl.311S.